The Seventh Annual UNC Conference on Melanoma: A Multidisciplinary Perspective for Health Care Providers


This conference will be held on Thursday, February 16, 2012 from 8:00 a.m. - 4:20 p.m. at the William and Ida Friday Center for Continuing Education. It will provide the latest information on diagnosing and treating melanoma and aggressive non-melanoma skin cancers with a focus on:

  • scientific evidence for sunscreens;
  • clinical dilemmas with diagnosing difficult melanocytic lesions;
  • surgical issues when treating melanoma and merkel cell cancers;
  • the tanning bed controversy as viewed by a North Carolina lawmaker; and
  • the current role of systemic therapy in the melanoma patient with metastatic disease.

To register online to attend the Conference on Melanoma, click here. All registrations must be received by February 3, 2012. For more information, view the conference brochure.


Dan Zedek, MD, will discuss "Pigmented Lesions of the Nail" at the conference for health care providers.

Latest in Treatment and Support Focus of Melanoma Patient Day

Participants will hear from melanoma experts on a number of topics, from sunscreen use and indoor tanning to the latest clinical trials and treatments.


The symposium will be held on Wednesday, February 15, 2012 from 12:30 - 4:30 p.m. at the William and Ida Friday Center for Continuing Education.


Registration is free and is required by February 3, 2012. To register to attend the Melanoma Patient Day, click here or call 800-673-1290. For additional information, view the symposium brochure.

Nancy Thomas, MD, PhD, will discuss "Diagnosis of 'Pink' (Amelanotic) Melanoma" at the Melanoma Patient Day Symposium and "Clinical Features of BRAF and NRAS Mutant Melanomas" at the conference for health care providers.

P Rex-1 protein key to melanoma metastasis

The team found that mice lacking the P-Rex1 protein are resistant to melanoma metastases.  When researchers tested human melanoma cells and tumor tissue for the protein, P-Rex1 was elevated in the majority of cases – a clue that the protein plays an important role in the cancer’s spread.

“Pinpointing that P-Rex1 plays a key role in metastasis gives us a better understanding of how vemurafenib may work and a target for developing new treatments,” says Nancy Thomas, MD, PhD, a professor of dermatology and member of UNC Lineberger. Read more.


Multidisciplinary research urged for optimal melanoma surgery

In recent editorial published in The Lancet, UNC Lineberger member David Ollila, MD, and co-author John Thompson, MD, of the Melanoma Institute Australia, praise a new study on optimal margins for melanoma surgery but urge researchers to bring new molecular and genetic techniques to bear on the question of how to minimize the need for more complex surgical techniques while maximizing long-term patient survival.


Dr. Ollila is a professor in the division of surgical oncology at UNC-Chapel Hill.  He just returned from the University of Sydney (Australia) and the Melanoma Institute Australia where he was a visiting scholar for six months. Read more.

UNC Lineberger    N.C. Cancer Hospital    Clinical Trials     Clinical Programs    Comprehensive Cancer Support


For questions about all clinical trials at UNC (including those at UNC that are also offered at other sites), contact the UNC Lineberger protocol office at 919-966-4432 or (toll-free) 1-877-668-0683.


To make an appointment at the N.C. Cancer Hospital for one of your patients, visit our web page for referring physicians. You may also contact the Carolina Consultation Center at 1-800-862-6264.